FLT3 inhibition in acute myeloid leukaemia

被引：11

作者：

Daver, Naval ^{[1
]}

Kantarjian, Hagop ^{[1
]}

机构：

[1] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

LANCET ONCOLOGY | 2017年 / 18卷 / 08期

关键词：

MUTATIONS; THERAPY;

D O I：

10.1016/S1470-2045(17)30509-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：988 / 989

页数：2

共 10 条

[1]

[Anonymous], 2014, BLOOD, DOI DOI 10.1182/BLOOD.V124.21.389.389

[2] Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML) [J].

Cortes, Jorge E. ;

Tallman, Martin S. ;

Schiller, Gary ;

Trone, Denise ;

Gammon, Guy ;

Goldberg, Stuart ;

Perl, Alexander E. ;

Marie, Jean Pierre ;

Martinelli, Giovanni ;

Levis, Mark .

BLOOD, 2013, 122 (21)

[3] Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status [J].

Cortes, Jorge E. ;

Kantarjian, Hagop ;

Foran, James M. ;

Ghirdaladze, Darejan ;

Zodelava, Mamia ;

Borthakur, Gautam ;

Gammon, Guy ;

Trone, Denise ;

Armstrong, Robert C. ;

James, Joyce ;

Levis, Mark .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) :3681-+

[4] Secondary mutations as mediators of resistance to targeted therapy in leukemia [J].

Daver, Naval ;

Cortes, Jorge ;

Ravandi, Farhad ;

Patel, Keyur P. ;

Burger, Jan A. ;

Konopleva, Marina ;

Kantarjian, Hagop .

BLOOD, 2015, 125 (21) :3236-3245

[5] Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study [J].

Deininger, Michael W. ;

Cortes, Jorge E. ;

Kantarjian, Hagop M. ;

Shah, Neil ;

Bixby, Dale ;

Mauro, Michael J. ;

Flinn, Ian W. ;

O'Hare, Thomas ;

Hu, Simin ;

Dorer, David J. ;

Rivera, Victor M. ;

Clackson, Tim ;

Turner, Christopher D. ;

Haluska, Frank G. ;

Druker, Brian J. ;

Talpaz, Moshe .

BLOOD, 2012, 120 (21)

[6] Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study [J].

Perl, Alexander E. ;

Altman, Jessica K. ;

Cortes, Jorge ;

Smith, Catherine ;

Litzow, Mark ;

Baer, Maria R. ;

Claxton, David ;

Erba, Harry P. ;

Gill, Stan ;

Goldberg, Stuart ;

Jurcic, Joseph G. ;

Larson, Richard A. ;

Liu, Chaofeng ;

Ritchie, Ellen ;

Schiller, Gary ;

Spira, Alexander I. ;

Strickland, Stephen A. ;

Tibes, Raoul ;

Ustun, Celalettin ;

Wang, Eunice S. ;

Stuart, Robert ;

Roellig, Christoph ;

Neubauer, Andreas ;

Martinelli, Giovanni ;

Bahceci, Erkut ;

Levis, Mark .

LANCET ONCOLOGY, 2017, 18 (08) :1061-1075

[7] Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation [J].

Ravandi, Farhad ;

Alattar, Mona Lisa ;

Grunwald, Michael R. ;

Rudek, Michelle A. ;

Rajkhowa, Trivikram ;

Richie, Mary Ann ;

Pierce, Sherry ;

Daver, Naval ;

Garcia-Manero, Guillermo ;

Faderl, Stefan ;

Nazha, Aziz ;

Konopleva, Marina ;

Borthakur, Gautam ;

Burger, Jan ;

Kadia, Tapan ;

Dellasala, Sara ;

Andreeff, Michael ;

Cortes, Jorge ;

Kantarjian, Hagop ;

Levis, Mark .

BLOOD, 2013, 121 (23) :4655-4662

[8]

Stone RM., 2015, Blood, V126, P6, DOI DOI 10.1182/blood.V126.23.6.6

[9] Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD [J].

Takahashi, Koichi ;

Kantarjian, Hagop ;

Pemmaraju, Naveen ;

Andreeff, Michael ;

Borthakur, Gautam ;

Faderl, Stefan ;

Garcia-Manero, Guillermo ;

Pierce, Sherry ;

Luthra, Rajyalakshmi ;

Cardenas-Turanzas, Marylou ;

Estrov, Zeev ;

Ravandi, Farhad ;

Cortes, Jorge .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (05) :659-666

[10] Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis [J].

Thiede, C ;

Steudel, C ;

Mohr, B ;

Schaich, M ;

Schäkel, U ;

Platzbecker, U ;

Wermke, M ;

Bornhäuser, M ;

Ritter, M ;

Neubauer, A ;

Ehninger, G ;

Illmer, T .

BLOOD, 2002, 99 (12) :4326-4335

← 1 →